Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000371

Drug Information
NameTerazosin
Synonymsterazosin; A 45975; SPBio_002701; Terazosine [INN-French]; C07127; Blavin; Terazosine; MLS001201836; Terazosina; 63590-64-7; Terazosin (INN); Lopac0_001138; 63074-08-8 (hydrochloride); CHEBI:9445; NCGC00025191-03; SAM002589982; Terazosin [INN:BAN]; STK567029; MLS001305722; Terazosabb (TN); BPBio1_000840; HMS2090P21; Hytrin; MLS000069703; Flumarc; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; NCGC00016026-08; Terazosinum [INN-Latin]; Prestwick2_000751; LS-110234; STOCK4S-28262; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; 70024-40-7 (mono-hydrochloride, dihydrate); BRD-A22256192-003-03-7; Terazosina [INN-Spanish]; Prestwick3_000751; AC-11120; D08569; Hytracin; CHEMBL611; AC1L1K9W; Terazosabb; CPD000058309; Abbott 45975; CID5401; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; BSPBio_000762; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; Prestwick1_000751; A-45975; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; Prestwick0_000751; DB01162; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-; Trazosin HCl; Fosfomic; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; Vasomet; L000692; C19H25N5O4; SMR000058309; UNII-8L5014XET7; Terazosinum; MolPort-001-684-489
Trade NameHytrin
CompanyAbbott Laboratories
IndicationBenign prostatic hyperplasia
[ICD9: 600   ICD10: N40]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)2
4-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,2
0,21,22)
InChIKeyVCKUSRYTPJJLNI-UHFFFAOYSA-N
Canonical SMILESCOC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 63590-64-7
FormulaC19H25N5O4
PubChem Compound IDCID 5401.
PubChem Substance IDSID 9337.
ChEBI9445;
SuperDrug ATC IDG04CA03
SuperDrug CAS ID063590647;
TargetAlpha-1D adrenergic receptorAntagonist[2][3]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074823 To Reference
Ref 2Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95. To Reference
Ref 3Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nat Med. 2000 Dec;6(12):1388-94. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543